Breaking Finance News

A statement released earlier today by Zacks Investment Research about K2M Group Holdings Inc (NASDAQ:KTWO) bumps the target price to $20.00

Boasting a price of $18.00, K2M Group Holdings Inc (NASDAQ:KTWO) traded -0.11% lower on the day. With the last stock price close up 17.11% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. K2M Group Holdings Inc has recorded a 50-day average of $16.82 and a two hundred day average of $15.37. Volume of trade was down over the average, with 190,331 shares of KTWO changing hands under the typical 285,129

Zacks Investment Research bumped up the target of K2M Group Holdings Inc (NASDAQ:KTWO) to $20.00 stating a potential upside of 0.11%.

On Friday September 16, 2016, Gabelli released a statement for K2M Group Holdings Inc (NASDAQ:KTWO) bumped up the target price from $0.00 to $22.00 that suggested an upside of 0.28%.

Performance Chart

K2M Group Holdings Inc (NASDAQ:KTWO)

With a total market value of $0, K2M Group Holdings Inc has with a one year low of $10.10 and a one year high of $21.67 .

A total of 7 equity analysts have released a ratings update on KTWO. zero equity analysts rating the company a strong buy, zero brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $20.43.

General Information About K2M Group Holdings Inc (NASDAQ:KTWO)

K2M Group Holdings, Inc. is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company's spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions. Its products consist of implants, disposables and instruments, which are marketed and sold primarily to hospitals for use by spine surgeons. The Company's product portfolio contains over 70 product lines that are used in spine surgeries, minimally invasive spine (MIS) and degenerative surgeries. It markets or sells its products in the United States and over 36 other countries. The Company's technologies include MESA, Rail 4D, Quicket Deformity, CAPRI, SERENGETI, RAVINE, EVEREST, CASCADIA and tifix.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.